NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis

Taysha Gene Therapies, Inc. (TSHA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TSHA

$5.60

+$0.03 (+0.54%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TSHA with… →

TSHA Key Statistics

As of Sep 4, 2026
Trading
Open
$5.52
Previous Close
$5.57
Day's Range
5.42–5.61
52-Week Range
2.71–7.30
Volume
2.11M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.17
Valuation
Market Cap
$1.82B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
332.67
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.41
Financials (FY)
Revenue (FY)
$9.77M+17.28%
Net Income (FY)
−$109.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
325.83M
1-Year Return
+71.78%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
3.14M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TSHA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.82%
2025+217.92%
2024−2.26%
2023−21.68%
2022−80.60%
2021−56.10%
2020 (partial year)+10.31%

As of September 4, 2026.

TSHA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$9.77M−$109.00M−1115.3%
2024$8.33M−$89.30M−1071.6%
2023$15.45M−$111.57M−722.1%
2022$2.50M−$166.01M−6635.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$9.77M—−$110.50M−$109.00M−1115.3%
2024$8.33M—−$86.62M−$89.30M−1071.6%
2023$15.45M—−$71.37M−$111.57M−722.1%
2022$2.50M—−$126.03M−$166.01M−6635.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TSHA Valuation vs Biotechnology Median

Median of 656 stocks
MetricTSHABiotechnology medianvs median
P/S ratio332.6715.2621.8x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Taysha Gene Therapies, Inc. (TSHA) is capitalised at $1.82B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 99.

TSHA last closed at $5.60 on September 4, 2026. That is +$0.03 (+0.54%) against the previous close. Over the past 52 weeks the price has ranged from $2.71 to $7.30. The latest close sits 106.57% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $9.77M. Against the prior fiscal year total of $8.33M, that is a change of +17.28%. The same year closed with a net loss of $109.00M. The reported profit margin is 0%. Trailing earnings per share are −0.41.

Across the 4 fiscal years on file, revenue moves from $2.50M in 2022 to $9.77M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 332.67 times revenue. On price-to-sales that is 21.8 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +71.78%. Measured over 5 years, that is −22.16% a year compounded. The reported beta is 1.17. Daily returns over the trailing 6 years annualize to a volatility of 128.59%.

Growth & Income

No dividend is on file for TSHA.

Across the complete calendar years on file, 2025 returned +217.92% and 2022 returned −80.60%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the price is +1.82%.

Peer Comparison

Taysha Gene Therapies, Inc. (TSHA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Taysha Gene Therapies, Inc. TSHA $1.82B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Taysha Gene Therapies, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Visit website →